signal transduction inhibitor

sig·nal trans·duc·tion in·hib·i·tor

(STI) (sig'năl trans-dŭk'shŭn in-hib'i-tŏr)
Category or classification of anticancer drugs that inhibit the action of enzymes essential to the growth and survival of cancer cells while causing relatively little or no damage to noncancer cells.
Mentioned in ?
References in periodicals archive ?
APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug in Phase I/IIa clinical prostate trial that was initiated in August 2011.
Additionally, the first of the three drugs to enter the clinic will be APC-100, an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
The lead signal transduction inhibitor compound, perifosine, is an orally-active AKT inhibitor that is in several Phase II trials for multiple cancers.
Researchers say Glivec, developed by Novartis Oncology, acts as a signal transduction inhibitor, a new class of drugs that can interfere with cell signaling pathways implicated in tumor development.
Adamis' APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug.
The integrative model for the mechanism of action suggests PCK3145 to be a signal transduction inhibitor with multiple ways (apoptosis, anti-angiogenesis and anti-metastasis) to restrict disease development.
We believe the angiogenesis and signal transduction inhibitor classes will provide the greatest revenue potential, congruent with their combined clinical and commercial appeal.
The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter.
In this collection of 11 articles, contributors describe their work in PTKs in such areas as using PTKs as targets for cancer and other indications, targeting Src homology 2 domains in drug discovery, using P12-kinase inhibition as a target for therapeutic intervention, using an activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia and JAK kinases in leukemia, lymphomas and multiple myeloma, applying platelet-derived growth factor, using a targeted therapy for myelogenous leukemia, testing signal transduction inhibitors in animal models of cancer, and using phosphoproteomics in drug discovery and development.
Signal transduction inhibitors, a new class of cancer drugs targeting solid tumors without the toxic side effects of chemotherapy, are causing treatment-resistant folliculitis in up to 75% of patients.
The most common target of the currently approved signal transduction inhibitors is the human epidermal growth factor 1 receptor, a receptor frequently overexpressed by cancer cells.
The company has established small molecule drug discovery programs focused on discovering and developing signal transduction inhibitors for the treatment of autoimmune/inflammatory diseases and cancer.

Full browser ?